Au­to­lus ex­tends the biotech IPO hot streak, adding $150M and bring­ing 2-day tal­ly to $718M

7 years ago
Financing

Lat­est rank­ing of top re­search in­sti­tu­tions show Chi­na com­ing on strong — with sig­nif­i­cant im­pli­ca­tions for biotech

7 years ago
R&D
China

AdoRx rais­es $10M for adeno­sine pro­gram in can­cer; Mol­e­c­u­lar Part­ners poach­es Re­gen­eron, re­cruit­ing Pamela Trail as ...

7 years ago
News Briefing

On a win­ning streak, Heron rock­ets up 30% on PhI­Ib pain drug da­ta

7 years ago
R&D

Mauled by a ma­jor set­back, In­cyte is point­ing to a bet­ter fu­ture — but con­cedes it al­so had to scrap an­oth­er failed ...

7 years ago
R&D

No­vo Nordisk’s 'se­ma' whips Mer­ck’s di­a­betes drug ri­val in PhI­II as it reach­es for best-in-class rank­ing for ...

7 years ago
R&D

Ex-Puma ex­ec sen­tenced to prison stretch on in­sid­er-trad­ing con­vic­tion — 'greed' made me do it

7 years ago
People
Pharma

Six biotechs crowd in­to Nas­daq, rais­ing $568M as the IPO par­ty con­tin­ues to lure com­pa­nies to Wall Street

7 years ago
Financing

Step right up: A biotech may soon sell an ex­per­i­men­tal med to dy­ing ALS pa­tients un­der 'Right to Try'

7 years ago
Bioregnum
R&D

Bio­phar­ma ri­vals at Roche and Bay­er both stand to ben­e­fit from the trend to­ward in­creased test­ing of can­cer pa­tients

7 years ago
R&D

Buf­fett, Di­mon and Be­zos find their mir­a­cle man, charged with fix­ing a bro­ken health­care sys­tem

7 years ago
People

Cel­gene/Re­cep­tos ex­ec jumps to Ku­ra as new COO; TG Ther­a­peu­tics al­lies with Novim­mune on $185M bis­pe­cif­ic deal

7 years ago
News Briefing

No­vo takes on gut-brain ax­is dis­cov­ery with Kally­ope, fo­cus­ing on obe­si­ty and di­a­betes

7 years ago
R&D
Pharma

GSK vs Gilead: Heavy­weight HIV fight will come down to a big show­down in Am­s­ter­dam next month

7 years ago
R&D

With an As­traZeneca can­cer drug in one hand, $37M in the oth­er, Shang­hai's Al­pha Bio zooms in­to a PhII study

7 years ago
Financing
Startups

I/O play­er iTeos lines up a $75M round as it preps for hu­man stud­ies, plans a leap to US hub

7 years ago
Financing
Startups

Ani­ka Ther­a­peu­tics shares crater as its 2nd PhI­II OA study flops -- drug com­bo pales in com­par­i­son to a steroid

7 years ago
R&D

Ver­tex ex­pands its San Diego R&D hub, adding a new wing for col­lab­o­ra­tors as it cen­ters on CF re­search

7 years ago
Financing
R&D

Build­ing up its rare obe­si­ty pipeline, Rhythm Phar­ma to raise $150M

7 years ago
R&D

Alex­ion shoots for fast re­view of Soliris suc­ces­sor us­ing a PRV; San­doz wades in­to med­ical cannabis busi­ness

7 years ago
News Briefing

Sarep­ta leads off Duchenne MD gene ther­a­py study with a ‘home run’ on ef­fi­ca­cy — but can they de­liv­er in 2 ...

7 years ago
R&D
Cell/Gene Tx

Mega-mon­ey biotech round spills $116M in­to gene ther­a­py up­start Free­line

7 years ago
Financing

De­ter­mined to build the lead­ing biotech play­er in a new R&D space, Steven Holtz­man lines up $55M for the next stage ...

7 years ago
Financing
Cell/Gene Tx

Re­plac­ing lab rats? Bay Area tech fund backs Em­u­late's $36M round to com­mer­cial­ize 'or­gan chip' tech

7 years ago
Financing
Discovery
First page Previous page 1018101910201021102210231024 Next page Last page
A service from the Financial Times